Psoriasis - New insights into pathogenesis and treatment;Psoriasis - Neue erkenntnisse zur pathogenese und therapie

Deutsches Arzteblatt

Volumn 106, Issue 1-2, 2009, Pages 11-19

  Mrowietz, Ulrich ^a,c   Reich, Kristian ^b  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Dermatologikum Hamburg ^*  (Germany)

^c Abteilung Dermatologie Venerologie und Allergologie   (Germany)

Author keywords

Genetics; Guidelines; Immune mediated inflammatory disease; Psoriasis; Treatment concept

Indexed keywords

ADALIMUMAB; CALCIPOTRIOL; CORTICOSTEROID; CYCLOSPORIN; DITHRANOL; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMARIC ACID; INFLIXIMAB; METHOTREXATE; TACALCITOL;

DISEASE COURSE; DRUG EFFECT; DRUG EFFICACY; PATHOGENESIS; PHOTODYNAMIC THERAPY; PROGNOSIS; PSORIASIS; PUVA; REVIEW;

DERMATOLOGY; HUMANS; PSORIASIS;

EID: 58549086961     PISSN: 00121207     EISSN: None     Source Type: Journal    
DOI: 10.3238/arztebl.2009.0011     Document Type: Review

References (25)

1. Henseler T, Christophers E: Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985; 13: 450-6.
2. Reich K, Hüffmeier U, König IR et al.: TNF polymorphisms in psoriasis: association of psoriatic arthritis with the promoter polymorphism TNF*-875 independent of the PSORS1 risk allele. Arthritis Rheum 2007; 56: 2056-64.
3. Cargill M, Schrodi SJ, Chang M et al.: A large-scale genetic association study confirms IL12B and leads to the identification of IL23R as psoriasis-risk genes. Am J Hum Genet 2007; 80: 273-90.
4. Diluvio L, Vollmer S, Besgen P, Ellwart JW, Chimenti S, Prinz JC: Identical TCR beta-chain rearrangements in streptococcal angina and skin lesions of patients with psoriasis vulgaris. J Immunol 2006; 176: 7104-11.
5. Fry L, Baker BS: Triggering psoriasis: the role of infections and medications. Clin Dermatol 2007; 25: 606-15.
6. Schröder JM, Reich K, Kabashima K et al.: Who is really in control of skin immunity under physiological circumstances - lymphocytes, dendritic cells or keratinocytes? Exp Dermatol 2006; 15: 913-29.
7. Harder J, Schröder JM: Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J Leukoc Biol 2005; 77: 476-86.
8. Sampogna F, Gisondi P, Melchi CF et al.: Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004; 151: 594-9.
9. Gladman DD, Antoni C, Mease P, Clegg DO, Nash P: Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis 2005; 64 (Suppl 2): ii14-7.
10. Soriano ER, McHugh NJ: Therapies for peripheral joint disease in psoriatic arthritis. A systematic review. J Rheumatol 2006; 33: 1422-30.
11. Nast A, Kopp IB, Augustin M et al.: Evidence-based (S3) guidelines for the treatment of psoriasis vulgaris. J Dtsch Dermatol Ges 2007; 5 (Suppl 3): 1-119.
12. Finlay AY: Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-7.
13. Smith CH, Anstey AV, Barker JN et al.; British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005; 153: 486-97.
14. Reich K, Mrowietz U: Treatment goals in psoriasis. J Dtsch Dermatol Ges 2007; 5: 566-74.
15. Mrowietz U, Elder JT, Barker J: The importance of disease associations and concomitant therapy for the long-term management of psoriasis patients. Arch Dermatol Res 2006; 298: 309-19.
16. Ludwig RJ, Herzog C, Rostock A et al.: Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol 2007; 156: 271-6.
17. Sommer DM, Jenisch S, Suchan M, Christophers E, Weichenthal M: Increased prevalence of the metabolic syndrome in patients with moderate to severe psoriasis. Arch Dermatol Res 2006; 298: 321-8.
18. Gisondi P, Tessari G, Conti A et al.: Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case-control study. Br J Dermatol 2007; 157: 68-73.
19. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB: Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
20. Mallbris L, Akre O, Granath F et al.: Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol 2004; 19: 225-30.
21. Dubertret L, Mrowietz U, Ranki A et al.: European patient perspectives on the impact of psoriasis: the EUROPSO patient membership survey. Br J Dermatol 2006; 155: 729-36.
22. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM: Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41(3 Pt 1): 401-7.
23. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K: Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology 2008; 216: 366-72.
24. Naldi L, Parazzini F, Brevi A, et al.: Family history, smoking habits, alcohol consumption and risk of psoriasis. Br J Dermatol. 1992; 127: 212-7.
25. Kragballe K, Austad J, Barnes L et al.: Efficacy results of a 52-week, randomised, double-blind, safety study of a calcipotriol/betamethasone dipropionate two-compound product (Daivobet/Dovobet/Taclonex) in the treatment of psoriasis vulgaris. Dermatology 2006; 213: 319-26.